Trial · NCT02667886
Participant flow60
How many started, completed or left each group, period by period.
1 to 20 of 60
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dose Escalation (Part A) | STARTED | Dose Escalation (Part A): X4P-001 200 mg BID With Axitinib | 3 | |
| Dose Escalation (Part A) | STARTED | Dose Escalation (Part A): X4P-001 400 mg QD With Axitinib | 7 | |
| Dose Escalation (Part A) | STARTED | Dose Escalation (Part A): X4P-001 600 mg QD With Axitinib | 6 | |
| Dose Escalation (Part A) | STARTED | Dose Expansion (Part B): X4P-001 400 mg QD With Axitinib | 0 | |
| Dose Escalation (Part A) | STARTED | Dose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy | 0 | |
| Dose Escalation (Part A) | Received at Least 1 Dose of Study Drug | Dose Escalation (Part A): X4P-001 200 mg BID With Axitinib | 3 | |
| Dose Escalation (Part A) | Received at Least 1 Dose of Study Drug | Dose Escalation (Part A): X4P-001 400 mg QD With Axitinib | 7 | |
| Dose Escalation (Part A) | Received at Least 1 Dose of Study Drug | Dose Escalation (Part A): X4P-001 600 mg QD With Axitinib | 6 | |
| Dose Escalation (Part A) | Received at Least 1 Dose of Study Drug | Dose Expansion (Part B): X4P-001 400 mg QD With Axitinib | 0 | |
| Dose Escalation (Part A) | Received at Least 1 Dose of Study Drug | Dose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy | 0 | |
| Dose Escalation (Part A) | COMPLETED | Dose Escalation (Part A): X4P-001 200 mg BID With Axitinib | 1 | |
| Dose Escalation (Part A) | COMPLETED | Dose Escalation (Part A): X4P-001 400 mg QD With Axitinib | 0 | |
| Dose Escalation (Part A) | COMPLETED | Dose Escalation (Part A): X4P-001 600 mg QD With Axitinib | 0 | |
| Dose Escalation (Part A) | COMPLETED | Dose Expansion (Part B): X4P-001 400 mg QD With Axitinib | 0 | |
| Dose Escalation (Part A) | COMPLETED | Dose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy | 0 | |
| Dose Escalation (Part A) | NOT COMPLETED | Dose Escalation (Part A): X4P-001 200 mg BID With Axitinib | 2 | |
| Dose Escalation (Part A) | NOT COMPLETED | Dose Escalation (Part A): X4P-001 400 mg QD With Axitinib | 7 | |
| Dose Escalation (Part A) | NOT COMPLETED | Dose Escalation (Part A): X4P-001 600 mg QD With Axitinib | 6 | |
| Dose Escalation (Part A) | NOT COMPLETED | Dose Expansion (Part B): X4P-001 400 mg QD With Axitinib | 0 | |
| Dose Escalation (Part A) | NOT COMPLETED | Dose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02667886/flow